Lymphoma

Protocol NumberSponsorProtocol Title
NCT01799889

Gilead Sciences
GS-US-339-0102
A Phase II, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies


NCT01996865


Celgene Corporation
CC-5013-NHL-008
A Phase 3B Multi-Center Randomized, Open-Label Study of Lenalidomide (CC-5013) Plus Rituximab Compared to Lenalidomide Plus Rituximab Followed by Lenalidomide Maintenance in Subjects with Relapsed/Refractory Follicular, Mantle Cell and Marginal Zone Lymphoma (MAGNIFY)

NCT02600897Hoffmann-La Roche
GO29834, 2015-001999-22
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

The treatment of malignant lymphoma is rapidly advancing. Northwest Georgia Oncology Centers is currently conduction multiple trials in multiple lymphoma subtypes. These include the use of such novel agents as new-generation monoclonal antibodies, targeted agents and immune modifiers.